摘要
胃肠道(GI)肿瘤是全球癌症患者死亡的主要原因之一。特别是,胃癌(GC)是癌症死亡的第三个原因,而食管肿瘤是全球第八大主要癌症,其发病率尤其是腺癌类型在不断增加。此外,肝细胞癌,胆管癌和胰腺癌是多学科方法的一个非常有趣的模型,最近新药被用于治疗。目前,新的临床试验被设计成包括与小分子抑制剂(即酪氨酸激酶抑制剂)和/或单克隆抗体(即抗EGFR抗体)联合的经典化疗。此外,这个问题还包括一个用于靶向治疗的新分子的综合列表。新的治疗模式(多学科方法)和靶向治疗方法的发展有助于改善这些癌症疾病的结果。在过去几年中,恶性肿瘤的分子生物学,特异性靶点的发现以及由此产生的阻断关键激酶和几种分子途径的全身性药物的开发都取得了令人瞩目的进展,这些都促进了癌症治疗的进展,同样在GI非结直肠癌癌症治疗。
关键词: 胃肠癌,目标疗法,临床方面,治疗,预后因素,转移,费用
图形摘要
Current Cancer Drug Targets
Title:The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration
Volume: 18 Issue: 5
关键词: 胃肠癌,目标疗法,临床方面,治疗,预后因素,转移,费用
摘要: Gastrointestinal (GI) tumors are among the leading cause of death in cancer patients worldwide. Particularly, gastric cancer (GC) is the third cause of cancer deaths, whereas esophageal neoplasm is the eighth leading most common cancer worldwide and its incidence, especially adenocarcinoma type, is continuously increasing. Also, Hepatocellular carcinoma, Cholangiocarcinoma and pancreatic cancer represent a very interesting model to multidisciplinary approach and recently new drugs are used in their treatment. Currently, new clinical trials are designed including classic chemotherapy in association with either small molecule inhibitors (i.e. Tyrosine Kinase inhibitors) and/or monoclonal antibody (i.e. anti-EGFR antibody). Moreover, a comprehensive list of new molecules for target therapy is included in this issue. The development of new treatment modalities (multidisciplinary approach) and targeted therapy approaches have contributed to improving the outcome in these cancer diseases. During the past few years, remarkable progress in molecular biology of malignancy, the discovery of specific targets, and the resulting development of systemic drugs that block critical kinases and several molecular pathways have all contributed to progress in cancer treatment, also in GI non-colorectal cancer treatment.
Export Options
About this article
Cite this article as:
The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration, Current Cancer Drug Targets 2018; 18 (5) . https://dx.doi.org/10.2174/1568009617666170208162058
DOI https://dx.doi.org/10.2174/1568009617666170208162058 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Engineered Nanoparticles in Cancer Therapy
Recent Patents on Drug Delivery & Formulation Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Reviews on Recent Clinical Trials Novel Mechanisms of Anticancer Activities of Green Tea Component Epigallocatechin- 3-Gallate
Anti-Cancer Agents in Medicinal Chemistry Recent Advancement and Technological Aspects of Pulsatile Drug Delivery System - A Laconic Review
Current Drug Targets Prevention of Upper Gastrointestinal Ulcer and Complications in Low-Dose Aspirin Users
Current Pharmaceutical Design Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism The Impacts of Non-coding RNAs and N<sup>6</sup>-Methyladenosine on Cancer: Past, Present and Future
Current Cancer Drug Targets Serum Interleukin-33 as a Biomarker in Predicting Neonatal Sepsis in Premature Infants
Combinatorial Chemistry & High Throughput Screening A Compendium of Volatile Organic Compounds (VOCs) Released By Human Cell Lines
Current Medicinal Chemistry Cyclooxygenase Enzymes: Regulation and Function
Current Pharmaceutical Design Targeting Stem Cells-Clinical Implications for Cancer Therapy
Current Stem Cell Research & Therapy Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
Clinical Cancer Drugs The Role of Natural Products in the Ligand Deorphanization of TRP Channels
Current Pharmaceutical Design Microbiome Regulation of Autoimmune, Gut and Liver Associated Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Plant Secondary Metabolites in Cancer Chemotherapy: Where are We?
Current Pharmaceutical Biotechnology The Antiproliferative Effect of Soy (<i>Glycine max</i>) Isoflavones Contained in a Nutraceutical on Cancer Cell Lines
Current Nutraceuticals Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery Sequential Bilateral Internal Jugular Vein Thrombosis: A Case Report and Review of this Rare Medical Entity
Vascular Disease Prevention (Discontinued) Leukotriene A4 Hydrolase as a Target for Cancer Prevention and Therapy
Current Cancer Drug Targets Targeting of Antioxidant and Anti-Thrombotic Drugs to Endothelial Cell Adhesion Molecules
Current Pharmaceutical Design